Written during the midst of the SARS-CoV-2 pandemic, the challenges observed provide the backdrop for many of the observations.

This article by Dr. Andy Garret, EVP Scientific Operations, focuses on what others could learn from good statistical practices in drug development, and considers areas where drug development could benefit from some fresh thinking and challenge. In each section a recommendation(s) is made with the aim of challenging current thinking and practices.

Read article